As we brace for another winter, the threat of respiratory viruses looms large, impacting communities and healthcare systems alike. In the face of this challenge, Professor Nathan Bartlett, a virologist at the University of Newcastle, has dedicated his career to finding innovative solutions. His latest endeavor? A nasal spray that could revolutionize our approach to respiratory infections.
A Nasal Spray with a Difference
Professor Bartlett and his team have developed INNA-051, an investigational nasal spray that takes a unique approach to fighting respiratory viruses. Instead of targeting specific viruses, INNA-051 boosts the body's innate immune system, its first line of defense against infections. This strategy offers a broader spectrum of protection, potentially safeguarding against a range of respiratory infections, including influenza, RSV, and COVID-19.
From Discovery to Development
The journey of INNA-051 began with an unexpected observation by researchers at the Doherty Institute in Melbourne. They noticed that a compound originally intended to enhance vaccine effectiveness seemed to provide protection against influenza even without a vaccine. Professor Bartlett was then tasked with designing a program to validate these findings.
Over five years, Professor Bartlett and his colleagues at the University of Newcastle and HMRI, alongside collaborators in Australia and the UK, worked tirelessly to test the compound against various respiratory viruses. Their efforts laid the foundation for clinical development, attracting significant funding from organizations like the Gates Foundation and the Minderoo Foundation, as well as an $18 million contract with the US Department of Defense.
Clinical Trials and Beyond
The nasal spray is now in Phase 2 clinical trials in the United States. Following a successful safety study involving 200 participants, a larger trial with 900 people is planned for later this year. The study will focus on individuals at higher risk of exposure to respiratory viruses, such as those living in university accommodations, households with young children, and childcare settings.
For Professor Bartlett, this progress is not just a scientific milestone but a step towards making a real difference in people's lives. He envisions the nasal spray protecting those most vulnerable to severe outcomes from respiratory infections.
A Reminder to Stay Vigilant
As winter approaches, recent data from FluTracking highlights a rise in respiratory illness activity across Australia. This serves as a stark reminder that we cannot afford to let our guard down when it comes to respiratory viruses. While new treatments and preventions are crucial, Professor Bartlett emphasizes the importance of simple public health measures.
"Vaccination is key to protecting yourself and those around you from serious illness," he says. "Staying home when unwell, practicing good hand hygiene, and avoiding close contact with vulnerable individuals are small actions that can have a significant impact on protecting our communities."
Conclusion
Professor Bartlett's work showcases the power of scientific innovation in the fight against respiratory viruses. While we eagerly await the results of clinical trials, his research serves as a reminder that a combination of innovative treatments and simple public health measures is our best defense against these seasonal threats.
